Trial Profile
A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Vincristine
- Indications Soft tissue sarcoma
- Focus Adverse reactions
- 01 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 01 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 01 Sep 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.